Farmington, CT, December 14, 2023– CaroGen Corporation, a developer of transformative immunotherapies for cancer and infectious diseases, announced today that preclinical data on CARG-2020, its flagship immuno-oncology clinical candidate for ovarian cancer, has been published in the Journal of Cancer Immunology Research (Alvero et al. Cancer Immunol Res (Dec. 2023, in press)).